Current Report Filing (8-k)
July 16 2015 - 4:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): July 14, 2015
NEKTAR
THERAPEUTICS
(Exact
Name of Registrant as Specified in Charter)
Delaware |
0-24006 |
94-3134940 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
455
Mission Bay Boulevard South
San
Francisco, California 94158
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (415) 482-5300
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Certain
executive officers of Nektar Therapeutics (“Nektar”) have adopted stock trading plans in accordance with guidelines
specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and the corporate policies of Nektar. These stock
trading plans provide for the orderly management of expiring stock options held by the executive officers. Because these plans
were established in advance of any trade being made pursuant to the plans, they help avoid concerns about whether an executive
officer had material, non-public information at the time he or she entered into the trading plan. The stock option exercise and
same-day sale transactions by each executive officer pursuant to Rule 10b5-1 plans will be publicly disclosed through Form 4 filings
with the U.S. Securities and Exchange Commission.
In
May 2015, Howard W. Robin, the President and Chief Executive Officer of Nektar, adopted a new stock trading plan (the “Expiring
Option Plan”) that provides for the exercise and same-day sale of certain expiring stock options held by Mr. Robin on a monthly
pro-rata basis over the six month period prior to each option expiration date. The first exercise and same day sale of stock options
under the Expiring Option Plan was made on July 14, 2015.
SIGNATURES
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
|
|
|
By: |
|
/s/
Gil M. Labrucherie |
|
|
Gil
M. Labrucherie |
|
|
General
Counsel and Secretary |
|
|
Date: |
|
July
16, 2015
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Sep 2023 to Sep 2024